Currently, the main applications of HDAC inhibitors (HDACis) are limited to the treatment of peripheral T-cell lymphoma and cutaneous T-cell lymphoma, whereas the development of drugs for solid tumors is relatively limited. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.